| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
- locally advanced or metastatic adrenocortical carcinoma (ACC)
- malignant pheochromocytoma/paraganglioma (MPP) |
|
| E.1.1.1 | Medical condition in easily understood language |
- locally advanced or metastatic adrenocortical carcinoma (ACC)
- malignant pheochromocytoma/paraganglioma (MPP) |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
| MedDRA Classification |
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | PT |
| E.1.2 | Classification code | 10001388 |
| E.1.2 | Term | Adrenocortical carcinoma |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.1 |
| E.1.2 | Level | LLT |
| E.1.2 | Classification code | 10034876 |
| E.1.2 | Term | Pheochromocytoma |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.2 Medical condition or disease under investigation |
| E.1.2 | Version | 20.0 |
| E.1.2 | Level | LLT |
| E.1.2 | Classification code | 10075444 |
| E.1.2 | Term | Malignant paraganglioma |
| E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| E.1.3 | Condition being studied is a rare disease | Yes |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
The primary objective of this trial is to evaluate safety and tolerability of
EO2401 in combination with nivolumab in patients with unresectable,
previously treated, and previously untreated, locally advanced or
metastatic ACC, and progressive MPP. |
|
| E.2.2 | Secondary objectives of the trial |
The secondary objectives include assessment of:
- immunogenicity in relation to T cells of EO2316, EO2317, EO2318, and
UCP2 that compose EO2401; T cell cross-reactivity with the human TAAs
IL13Rα2, FOXM1, and BIRC5/surviving will also be evaluated,
- objective response rate (ORR) and duration of response (DOR), and
- progression-free survival (PFS) and overall survival (OS). |
|
| E.2.3 | Trial contains a sub-study | No |
| E.3 | Principal inclusion criteria |
1. For inclusion in Cohort 1 patients should have adrenocortical
carcinoma, or malignant pheochromocytoma/paraganglioma, as defined
below for Cohorts 2A and 3A.
2. For inclusion in Cohorts 2A and 2B patients should have histologically
confirmed (at primary diagnosis) unresectable locally advanced or
metastatic (ENSAT/AJCC] stage 3 = tumor has spread into nearby
tissues or lymph nodes, or stage 4 = metastatic disease) adrenocortical
carcinoma.
a. In addition, for inclusion in Cohort 2 A patients should also have
received treatment with at least one line, but not more than two prior
lines, of systemic therapy including mitotane and/or chemotherapy
(other groups of systemic therapies utilized in e.g. clinical trials will also
be assessed and counted if appropriate).
b. In addition, for inclusion in Cohort 2B patients should not have
received prior systemic therapy for their adrenocortical carcinoma.
Note, adjuvant therapy for patients with complete resections should not
be counted in the definitions above.
3. For inclusion in Cohorts 3A and 3B patients should have histologically
confirmed (at primary diagnosis) unresectable malignant (defined as
metastatic disease, i.e. presence of chromaffin tissue in non-chromaffin
organs pheochromocytoma/paraganglioma, and RECIST defined
progression should have been documented during a maximum of an
18months period.
a. In addition, for inclusion in Cohort 3A patients should also have
received treatment with at least two prior lines of systemic therapy
including radionuclide therapy and/or chemotherapy (other groups of
systemic therapies utilized in e.g. clinical trials will also be assessed and
counted if appropriate).
b. In addition, for inclusion in Cohort 3B patients should not have
received prior systemic therapy for their malignant pheochromocytoma/paraganglioma.
4. Patients with an age ≥ 18 years old.
5. Patients who are human leukocyte antigen (HLA)-A2 positive.
6. Patients with an Eastern Cooperative Oncology Group (ECOG)
performance status ≤ 2 (see Section 12.2 [39]).
7. Patients with a life expectancy > 4 months as judged by their treating
physician.
8. Patients with at least one measurable lesion according to RECIST 1.1
(see Section 12.1).
9. Males or non-pregnant, non-lactating, females who are:
e) female, post-menopausal (serum follicle-stimulating hormone (FSH)
level > 40 mIU/mL >),
f) female and male, surgically sterile (e.g. bilaterally blocked or removed
fallopian tubes, vas deferens),
g) female of childbearing potential with a negative highly sensitive
serum pregnancy test within 72 hours prior to first administration of
study treatment and use of a highly effective contraception from signing
the Informed Consent Form (ICF) through 5 months after the last study
treatment dose administered; note, the male partner should in addition
to the use of highly effective contraception by the female patient also
use condoms,
h) male patient with female partners of childbearing potential must use
condoms from signing the ICF through 5 months after the last study
treatment dose administered; in addition, male patients must ensure
that their partners of childbearing potential also use highly effective
contraception.
Highly effective barrier and non-barrier contraception include:
i) combined (estrogen and progesterone containing) hormonal
contraception associated with inhibition of ovulation: oral, intravaginal,
transdermal,
ii) progestogen-only hormonal contraception associated with inhibition
of ovulation: oral, injectable, implantable, intrauterine device, and
iii) sexual abstinence when in line with the preferred and usual lifestyle
of the patient (e.g. periodic abstinence is not considered a highly
effective method).
10. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
11. Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures. Note, a 2-stage consent procedure is going to be used in the trial (see Section 4.2); the first minimized consent related to the procedure of HLA-testing, and the second to all other trial details and procedures. |
|
| E.4 | Principal exclusion criteria |
1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2401 administration, unless required to treat an adverse event. Note, inhaled steroids and adrenal replacement steroid doses > 13 mg daily prednisone equivalents are permitted. Thus, patients needing hydrocortisone replacement therapy due to prior or ongoing mitotane therapy can receive hydrocortisone doses > 53 mg/day, i.e. also in the normally used range of 60-80 mg/day, and still be included in the trial.
2. Patients with prior treatment with compounds targeting PD-1, PD-L1,
CTLA-4, or similar compounds where general resistance against
therapeutic vaccination approaches might have developed (e.g. defects
to the cellular antigen processing/presentation machinery, including
mutations in Janus kinas [JAK] 1, JAK2, and β-2-microglobulin [B2M])
allowing tumor cells to avoid recognition and attack by immune cells.
3. Patients with prior exposure to EO2401, e.g. patients treated in Cohorts 2B or 3B of the current trial cannot be re-enrolled for treatment also in Cohorts 2A or 3A.
4. Patients treated with immunotherapy (meaning immunostimulatory or
immunosuppressive therapy; beside excluded, or allowed, compounds
per other inclusion/exclusion criteria specifications), radionuclide
therapy, radiotherapy, cytoreductive therapy, or received treatment with
any other investigational agent within 28 days before the first EO2401
administration. Note, for patients with ACC continued treatment with
mitotane during this trail is allowed provided tumor progression on this
therapy has been demonstrated under therapeutic plasma level or at
maximum individual tolerated dose and mitotane plasma level
monitoring is maintained during the trial (mitotane might have been
given in the adjuvant and/or established disease settings as long as
progression on this therapy before trial inclusion has been documented).
For patients with MPP, concurrent therapy with octreotide is allowed
provided tumor progression on this therapy has been demonstrated;
concurrent therapy with bisphosphonates (e.g. zoledronic acid) or
denosumab is also allowed.
5. Patients with ACC with more than three organs involved by disease,
combined with high ki-67 expression in tumor (≥ 20%), and
unresectable primary tumor.
6. Patients with ACC and uncontrolled cortisol secretion (according to
the judgement of the treating physician).
7. Patients with MPP and uncontrolled blood pressure (according to the
judgement of the treating physician).
8. Patients with abnormal laboratory values according to the following
list (note, lab ranges according to the performing laboratory's reference
ranges):
a. hemoglobin < 10 g/dL (6.2 mmol/L) (transfusion to correct the value
is acceptable),
b. white blood cell count decrease (< 3.0 × 109/L),
c. absolute neutrophil count decrease (< 1.5 × 109/L),
d. platelet count decrease (< 75 × 109/L),
e. bilirubin > 1.5 x upper limit of normal (ULN) (note, benign hereditary
hyperbilirubinemia, e.g. Gilbert's syndrome is permitted),
f. alanine aminotransferase (ALT) > 3 x ULN; if disease metastatic to the
liver > 5 x ULN,
g. aspartate aminotransferase (AST) > 3 x ULN; if disease metastatic to
the liver > 5 x ULN,
h. serum creatinine increase (> 1.5 x ULN); however, if creatinine
clearance (measured, or calculated according to the Cockcroft/Gault
[40] formula; CCr={((l40–age) x weight)/(72xSCr)} x 0.85 (if female);
CCr (creatinine clearance) = mL/minute, age = years, weight = kg, SCr
(serum creatinine) = mg/dL) is > 40 mL/minute the patient can be
enrolled, and
i. abnormal thyroid function per local laboratory levels (note, patients
with hypothyroidism only requiring hormone replacement therapy are
permitted to enroll).
9. Patients with persistent Grade 3 or 4 toxicities (according to NCICTCAE
v5.0) after prior treatments; toxicities must be resolved since at
least 2 weeks before study treatment start to Grade 1 or less. However,
alopecia or other persisting toxicities Grade ≤ 2 not constituting a safety
risk based on Investigator's judgment are acceptable.
10. Uncontrolled central nervous system (CNS) metastasis; patients with
history of CNS metastases are eligible if CNS disease has been
radiographically and neurologically stable for at least 6 weeks prior to
ICF signing and do not require corticosteroids (of any dose; for the CNS
disease specifically) for symptomatic management.
11. Other malignancy or prior malignancy with a disease-free interval of
less than 3 years prior to ICF signing; except those treated with surgical
intervention and an expected low likelihood of recurrence such as basal
cell or squamous cell skin cancer, or carcinoma in situ, i.e. patients with
adequately treated basal cell or squamous cell skin cancer, or carcinoma
in situ are eligible. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
The primary endpoint regarding safety and tolerability of EO2401 in
combination with nivolumab is a descriptive medical assessment of the
combined profile of incidences of adverse events (AEs), treatmentemergent
AEs (TEAEs), serious AEs (SAEs), deaths, reasons for treatment discontinuation/delays, and laboratory abnormalities using the NCI-CTCAE v5.0 grading system. |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
AEs will be monitored throughout the study. AEs are collected from the date of the patient's signing the ICF until 30 days after the final administration of study drug. SAEs with a plausible causal relationship to study drug will be reported from the date of the patient's signing the ICF until indefinitely (regardless of time elapse from the final study drug administration). An AE causally not related to study drug will be monitored (followed-up) until resolution, stabilization, or end of the clinical trial. Clinically relevant laboratory abnormalities will be followed up until they return to normal or become stabilized (permanent condition). Any AE with a plausible causal relationship to study drug as well as all SAEs will be followed up until the event has resolved or
stabilized. |
|
| E.5.2 | Secondary end point(s) |
Secondary endpoints include:
• Percentage of patients with shown immunogenicity (expansion of
specific T cells comparing samples taken at baseline versus on treatment
n an individual patient determining if the patient has a positive response
to the immunization, or not) in relation to EO2316, EO2317, EO2318, and
UCP2 that compose EO2401 by interferon-gamma (IFN-γ) enzyme-linked
immunospot (ELISpot), and if needed by intracellular cytokines staining,
or multimers staining assays. Cross reactivities with the human TAAs
IL13Rα2, FOXM1, and BIRC5/survivin will also be evaluated by the same
methods.
• ORR and DOR as described by RECIST 1.1 and iRECIST criteria.
• PFS as described by RECIST 1.1 and iRECIST criteria, defined as the
time interval from the date of first study treatment administration to the
date of progression (by RECIST 1.1 or iRECIST criteria) or death due to
any cause, whichever is earlier. Patients without progression or death
are to be censored at the time of the last tumor assessment.
• OS defined as the time interval from the date of first study treatment
administration to the date of death due to any cause. Patients alive will
be censored at the date of the last documented follow-up. |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Percentage of patients with shown immunogenicity is evaluated on
Week 1, 5 , 7 , 11, 15 and 19, then every 4 weeks of treatment onwards.
Post treatment is evaluated on Day 30 and every 8 weeks before disease
progression
• Objective Response Rate (ORR) and Duration of Response (DOR) as
described by RECIST 1.1 and iRECIST criteria
• PFS as described by RECIST 1.1 and iRECIST criteria, defined as the
time interval from the date of first study treatment administration to the
date of progression (by RECIST 1.1 or iRECIST criteria) or death due to
any cause, whichever is earlier. Patients without progression or death
are to be censored at the time of the last tumor assessment. |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | No |
| E.6.7 | Pharmacodynamic | No |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | No |
| E.6.10 | Pharmacogenetic | Yes |
| E.6.11 | Pharmacogenomic | No |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | Yes |
| E.6.13.1 | Other scope of the trial description |
|
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | Yes |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | Yes |
| E.7.1.3.1 | Other trial type description |
| A phase Ib/II trial but another trial is the Fist in Human |
|
| E.7.2 | Therapeutic exploratory (Phase II) | Yes |
| E.7.3 | Therapeutic confirmatory (Phase III) | No |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | No |
| E.8.1.1 | Randomised | No |
| E.8.1.2 | Open | Yes |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | No |
| E.8.1.5 | Parallel group | No |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | Yes |
| E.8.1.7.1 | Other trial design description |
| The trial is a 5-cohort study |
|
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | No |
| E.8.2.2 | Placebo | No |
| E.8.2.3 | Other | No |
| E.8.2.4 | Number of treatment arms in the trial | 1 |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 8 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Denmark |
| France |
| Germany |
| Italy |
| Netherlands |
| Spain |
| Sweden |
| United States |
|
| E.8.7 | Trial has a data monitoring committee | Yes |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
| Last Visit Last Patient (LVLP) |
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 2 |
| E.8.9.1 | In the Member State concerned months | 6 |
| E.8.9.1 | In the Member State concerned days | 0 |
| E.8.9.2 | In all countries concerned by the trial years | 2 |
| E.8.9.2 | In all countries concerned by the trial months | 6 |
| E.8.9.2 | In all countries concerned by the trial days | 0 |
Print
